Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-6 of 6
Keywords: Plasminogen activator
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
M. Köhrmann, T. Nowe, H.B. Huttner, T. Engelhorn, T. Struffert, R. Kollmar, M. Saake, A. Doerfler, S. Schwab, P.D. Schellinger
Journal:
Cerebrovascular Diseases
Cerebrovasc Dis (2009) 27 (2): 160–166.
Published Online: 18 December 2008
... were treated with intravenous recombinant tissue-type plasminogen activator between April 2006 and April 2008. Data were extracted from a prospectively collected database. Baseline demographic data, and clinical, laboratory and imaging findings were analyzed. Outcome was assessed using the modified...
Journal Articles
Journal:
Cerebrovascular Diseases
Cerebrovasc Dis (2007) 24 (1): 1–10.
Published Online: 22 May 2007
... of the twelve studies. Symptom severity was an independent risk factor in three of the studies and advanced age, increased time to treatment, high systolic blood pressure, low platelets, history of congestive heart failure and low plasminogen activator inhibitor levels were found to be independent risk factors...
Journal Articles
Journal:
Cerebrovascular Diseases
Cerebrovasc Dis (2007) 23 (4): 304–308.
Published Online: 29 December 2006
... with acute ischemic stroke (AIS) and assessed the safety and efficacy of recombinant tissue plasminogen activator (rtPA) administration in a community-based setting. Methods: A retrospective review of patients >80 years (n = 341) admitted to a community stroke center with AIS were compared...
Journal Articles
Journal:
Cerebrovascular Diseases
Cerebrovasc Dis (2002) 13 (4): 279–284.
Published Online: 17 May 2002
... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Plasminogen activator Neuropsychology Myocardial ischemia Thrombolysis Tissue plasminogen activator (tPA) is a serine protease...
Journal Articles
Journal:
Cerebrovascular Diseases
Cerebrovasc Dis (1997) 7 (6): 318–323.
Published Online: 31 October 1997
... of symptomatic hemorrhagic complication after combined therapy does not seem to be markedly greater than after thrombolysis alone. Plasminogen activator Tissue type Heparin Cerebral infarction Hemorrhage Cerebrovascular Diseases M. Grond J. Rudolf M. Neveling C. Stenzei W.-D. Heiss Max-Planck-Instilul...
Journal Articles
Journal:
Cerebrovascular Diseases
Cerebrovasc Dis (1991) 1 (Suppl. 1): 124–128.
Published Online: 04 September 1991
...M. Hennerici; W. Hacke; R. von Kummer; C. Hornig; W. Zangemeister Eighteen patients were treated with 70 mg tissue plasminogen activator (t-PA) intravenously after the onset of acute severe cerebral ischemia: 10 suffered from vertebrobasilar occlusive disease and 8 had carotid territory strokes...